Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a slower oxytocin infusion prevent dangerous blood pressure drops in C-Sections?

NCT ID NCT07784478

Disease control Sponsor: Khyber Girls Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests two standard methods of giving oxytocin, a drug that helps the uterus contract after childbirth, during planned C-sections under spinal anesthesia. One group receives a quick injection, while the other gets a slow infusion over 15 minutes. The goal is to see which method causes less of a drop in blood pressure and other heart-related changes, while still effectively preventing heavy bleeding. The study involves 60 healthy pregnant women aged 18-40 with a single baby at full term.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxytocin (Syntocinon) given as a rapid intravenous bolus or slow intravenous infusion
What this could lead to
If successful, this could identify a safer way to give oxytocin during C-sections, reducing blood pressure drops and improving maternal safety.
What could go wrong
This is a small, early-stage trial, so results may not apply to all patients. Both methods carry risks like blood pressure changes, and the optimal approach may vary by individual.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult female patients aged 18 to 40 years * American Society of Anesthesiologists (ASA) physical status class I or II * Singleton pregnancy at 37 to 42 weeks gestational age * Scheduled for elective caesarean section under spinal anaesthesia * Written informed consent obtained Exclusion Criteria: * Patients with anticipated hemodynamic instability including severe preeclampsia/eclampsia, placenta previa with active bleeding, placental abruption, or hemorrhagic shock * Pre-existing cardiovascular disease including ischemic heart disease, valvular heart disease, cardiomyopathy, or arrhythmias * Baseline systolic blood pressure \< 100 mmHg or heart rate \> 100 bpm before spinal block * Known hypersensitivity to oxytocin * Failed spinal anaesthesia requiring conversion to general anaesthesia * Patients receiving medications that may alter the hemodynamic response to oxytocin (beta-blockers, calcium channel blockers, ACE inhibitors, or angiotensin receptor blockers) * Pre-existing anaemia (Hb \< 8 g/dL)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cesarean section are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypotensive disorder Postpartum Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cesarean section Hypotension Postpartum hemorrhage Spinal anesthesia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hayatabad Medical Complex / Khyber Girls Medical College

    Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.